Market News How it works Learn FAQ
| RCT 0.0827 8.67% | NU 12.59 -16.95% | EWZ 34.15 -19.82% | BBD 2.93 -28.01% | TGL 0.2427 9.57% | AZTR 1.53 113.99% | ITUB 7.7 -20.37% | XP 15.705 -48.36% | NVD 3.99 -4.77% | SRTM 0.3 -30.28% | WFF 0.0898 12.25% | SPCX 146.9 -0.40% | PBR 22.5 -13.99% | SHFS 0.094 -29.00% | SOXL 90.5 8.31% | INTC 90.47 4.04% | VALE 12 -3.23% | NVDA 216 2.39% | CLRO 4.97 52.92% | NOK 8.64 6.14% | JBLU 2.37 -9.71% | TSLL 10.76 10.25% | CRWV 55.19 1.76% | GCDT 0.1545 -12.27% | SOXS 47.98 -8.54% | RIG 6.53 1.87% | NWGL 0.0869 5.98% | ABEV 2.83 -14.24% | RWM 14.5 -0.34% | BITO 10.65 -1.66% | AAL 12.2 0.74% | GPUS 0.1785 5.68% | TSLG 5.38 10.47% | T 20.85 -0.38% | SGRY 23.25 47.62% | IREN 25.43 2.11% | INTR 4.68 -34.91% | SBS 4.73 -26.09% | NFLX 63.9 -2.96% | GRAB 2.71 -2.87% | TSLA 391.62 5.21% | QID 14.22 -2.27% | WULF 11.98 5.83% | TQQQ 68.43 3.23% | CIFR 7.71 -2.90% | RBNE 0.17 -10.53% | SID 0.9118 -22.73% | SPDN 8.5 -0.47% | VZ 43.1 -3.49% | LUCD 0.5007 21.82%
QLQualigen Therapeutics, Inc. logo

Qualigen Therapeutics, Inc. (QLGN)

NASDAQ Capital Market · Currency in USD
$3.21 ▲ +0.17 (+5.59%)
At close: Nov 18, 4:00 PM ET. Market closed.
$3.20 ▼ -0.01 (-0.31%)
After hours: Nov 18, 7:55 PM ET

Summary

Previous Close
$3.04
Open
$2.98
Day's Range
$2.86 – $3.34
52 Week Range
$1.61 – $8.81
Volume
368,768
Avg. Volume
2,645,879
Market Cap
$5.43M
Beta (5Y Monthly)
0.28
PE Ratio (TTM)
--
EPS (TTM)
-$1.26
Earnings Date
--
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
--

Profile: Qualigen Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
4
CEO
Kevin A. Richardson II
Website
qlgntx.com

Qualigen Therapeutics, Inc. is a biotechnology enterprise focused on advancing groundbreaking treatments for both cancer and infectious diseases. In addition to its developmental pipeline, the company offers FastPack, an efficient system designed for swift diagnostic testing. Its therapeutic candidates currently undergoing development include QN-302, an investigational compound targeting pancreatic ductal adenocarcinoma; QN-247, a DNA-coated gold nanoparticle formulated to combat various types of cancer; and RAS-F, a small-molecule inhibitor designed to block RAS oncogene protein-protein interactions, thereby impeding RAS mutations and suppressing tumor growth.

Earnings

DateEst.Actual
May 11, 2026-$70.00-$0.79Beat
Nov 14, 2025-$70.00-$4.68Beat
Aug 14, 2025–-$1.00
Jul 21, 2025–-$1.82
Nov 14, 2024–-$4.70
Aug 14, 2024–-$9.71

Get free alerts on QLGN and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.